BIIB Q3 2021 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.8B-17.7% YoY

Gross Profit

$2.3B81.6% margin

Operating Income

$800M28.8% margin

Net Income

$329M11.8% margin

EPS (Diluted)

$2.22

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

$805M

Free Cash Flow

$743M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$23.8B

Total Liabilities

$12.9B

Stockholders' Equity

$10.4B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$3.4B	-17.7%
Gross Profit	$2.3B	$2.9B	-22.5%
Operating Income	$800M	$1.1B	-26.4%
Net Income	$329M	$702M	-53.1%

Revenue Segments

MS Product Revenues

$1.6B44%

Fumarate

$620M18%

TYSABRI product

$523M15%

SPINRAZA

$444M13%

Interferon

$388M11%

Geographic Segments

Non-US

$1.2B56%

UNITED STATES

$974M44%